Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600358 | 1.00 | FOLH1 (0.57) | FOLH1CPB2SLC6A5ALDH1A1LMNA | |
| SCHEMBL4600727 | 0.88 | SLC6A5 (0.46) | FOLH1CPB2SLC6A5CA1CA2 | |
| SCHEMBL4600730 | 0.88 | SLC6A5 (0.46) | FOLH1CPB2SLC6A5CA1CA2 | |
| SCHEMBL4598877 | 0.88 | FOLH1 (0.57) | FOLH1CPB2SLC6A5ALDH1A1LMNA | |
| SCHEMBL4598870 | 0.88 | FOLH1 (0.57) | FOLH1CPB2SLC6A5ALDH1A1LMNA | |
| SCHEMBL4738184 | 0.87 | FOLH1 (0.62) | FOLH1CPB2LMNAC3AR1 | |
| SCHEMBL4738193 | 0.87 | FOLH1 (0.62) | FOLH1CPB2LMNAC3AR1 | |
| SCHEMBL4600272 | 0.85 | CPB2 (0.56) | CPB2SLC6A5ALDH1A1KDM4E | |
| SCHEMBL4600264 | 0.85 | CPB2 (0.56) | CPB2SLC6A5ALDH1A1KDM4E | |
| SCHEMBL4600558 | 0.85 | TGM2 (0.45) | FOLH1CPB2SLC6A5CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | FOLH1 771/4885CPB2 1198/4885SLC6A5 2604/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | FOLH1 1486/4885CPB2 1322/4885SLC6A5 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.